Botox, Juvederm sales lift Allergan in first quarter

[anonymous]

Allergan plc reported a 3% improvement in revenues to $3.7 billion for the first quarter of 2018 compared to the prior year period, driven by a 13% increase in its core business which includes the Botox and Juvederm brands.
Net loss for the quarter was $332.5 million or $0.99 per diluted share compared to $2.6 billion or $7.86 per diluted share for the same period last year. Adjusted EPS totaled $3.74.
US Specialized Therapeutics revenues grew 6.5% while U.S. General Medicine fell 9.1% compared to the prior year period. International revenues rose 9%.
Full article: https://news.alphastreet.com/allergan-1q-2018-results/

 

[anonymous]

Allergan plc reported a 3% improvement in revenues to $3.7 billion for the first quarter of 2018 compared to the prior year period, driven by a 13% increase in its core business which includes the Botox and Juvederm brands.
Net loss for the quarter was $332.5 million or $0.99 per diluted share compared to $2.6 billion or $7.86 per diluted share for the same period last year. Adjusted EPS totaled $3.74.
US Specialized Therapeutics revenues grew 6.5% while U.S. General Medicine fell 9.1% compared to the prior year period. International revenues rose 9%.
Full article: https://news.alphastreet.com/allergan-1q-2018-results/

Which Allergan brands are the lowest performing?

 

[anonymous]

The street remains unimpressed.

I've also seen this train wreck from the inside and I'm glad I'm out.

 

[anonymous]

The street wanted a solid strategic direction with an off loading of WH or other. Not dialogue about more worthless share buy backs etc. AGN will begin losing institutional investors and this stock price will tank even more because of it. Since late July 2015, Saunders has been able to lose over 50% of the stock price with his shoot by the hip idea of how to grow AGN. The street is tired of it.

 

[anonymous]

Great q1 report, then we get hit with the news we $700 million for a stinking pile of trash that will yield zero products. Then Brent goes dishrag on the call and provides limp wristed no- leadership babble... this stock is going to freefall

 

[anonymous]

While several reputable Botox/Juvederm veterans head for the exits. Read the writing on the wall people.

 

[anonymous]

While several reputable Botox/Juvederm veterans head for the exits. Read the writing on the wall people.[/QUOTE
Many more would be gone if they didn’t sign the non competes.

 

[anonymous]

Well that was foolish.

 

[anonymous]

Hmmm and then you don’t pay the
Salesforce that performs??? What a joke - 30 plus turnover Facial reps recently . . . Better places to be that appreciate their managers.

 

[anonymous]

The street remains unimpressed.

I've also seen this train wreck from the inside and I'm glad I'm out.

It's bad. People with half a brain are gone. Loyalists hanging on to the last railing on the deck of the Titanic are the ones left. Sad to see. Once a GREAT company, not a good company, a great one. Sad.